Early Detection and Prevention of Dementia

www.infomeditech.com

InfoMeditech

KFDS, Thai FDA Approved

We provide services to diagnose Alzheimer's disease through ‘Neuro I’, the quantitative analysis system for brain imaging (MRI). In addition, we have developed ‘Neuro AI’, the artificial intelligence version of Neuro I, and are currently in the process of registration for medical devices from the Ministry of Food and Drug Safety in Korea.Based on the results of various tests and the results of the Neuro I analysis, we are conducting research and development on the artificial intelligence systems for screening and identifying AD risk groups

Early detection and preemptive prevention are important because drugs for the treatment of dementia due to Alzheimer's disease have not yet been developed. We will develop brain health functional foods for cognitive improvement, dietary habits and lifestyle related (exercise, sleep) programs for prevention of dementia and software to support brain training and provide services to delay or prevent onset of AD and cognitive decline.

We have been developing a business that provides total solutions for dementia, such as 1) predicting the onset of dementia, including Alzheimer’s disease, 2) early diagnosis and 3) prevention & care services

Based on Genetic testing, Blood testing, Brain imaging, and Artificial intelligence (AI) technology, we have been developing technology to predict the risk of dementia caused by Alzheimer’s disease, diagnose it early stage, and to prevent it in advance.

Early Detection and Prevention of Dementia

2. Solution for Diagnosing Dementia due to Alzheimer's Disease

3. Solution for Preventing Dementia

MRI Brain Image Quantitative Analysis System

Alzheimer’s Disease Diagnosis AI System.

Genetic and blood test that are closely related to Alzheimer's disease, can help predict the risk and progression of dementia caused by Alzheimer's disease by age. We are currently conducting genetic test to predict dementia caused by Alzheimer’s disease using the patented method and are developing polygenic prediction methods for dementia and a method to diagnose Alzheimer’s disease by analyzing blood biomarkers.

1. Solution for Predicting Dementia due to Alzheimer's Disease

APOE+ Genetic Test

Cognition

FitnessBalance

StressNutrition

SleepDepression

BodyComposition

Lifestyle Age

Data Type Neuropsychological testBlood Genomic

data MRI(T1) fMRI CSF Aβ PETMMSE SNSB

Number of Sample

12,024 7,207 5,840 8,120 6,720 5,840 385 2,025

National Research Center for Dementia (NRCD) has the largest Asian dementia cohort, including dementia patients and InfoMeditech has a global exclusive license for it.

InfoMeditech is working with the following medical institutions to conduct proof and trial services to check newly developed efficacy and safety.

InfoMeditech is the unique company to develop Alzheimer’s disease prediction and diagnosis technology.Alzheimer’s disease prediction and diagnosis technology are based on the original technology secured through the implementation of the government tasks “Development of Brain Image Artificial Intelligence (ADAI)” and “Development of Big Data Analysis Convergence Technology and Medical Service Platform for Early Dementia Prediction.” It has been commercialized and is working with joint research institutes to develop new dementia diagnosis technology and prevention programs.

Technological Background

Largest Dementia Cohort and Database in Asia

Proof and Trial Service

Current status of Cohort data construction (2019. 6)

1st

2nd

3rd

Screening test for dementia risk groupN=12,024

Precisioncognitive testN=7,207

Blood test & MRIN=6,720

Data retention status of NRCD (2019. 6)

InfoMeditech has been developing and commercializing new dementia predictive diagnosis products based on the source technology obtained through joint research with the following research institutes.

Joint Research and Original Technology Development

12,00010,0008,0006,0004,0002,0000

2014

Screening test for dementia risk groupPrecision cognitive testBlood test & MRI

Data

2015 2016 2017 2018 2019

Jun

Sep

Dec

Mar

Jun

Sep

Dec

Mar

Jun

Sep

Dec

Mar

Jun

Sep

Dec

Mar

Jun

Sep

Dec

Mar

Jun

The most feared disease in the Elderlypopulation, Dementia.

What is the most feared disease inelderly population?

Typical 2 types of Dementia.

『Dementia Awareness Survey 2014』, National Institute of Dementia(NID)

Caused by cerebral blood circulation

Chronic brain disease with deterioration of cognitive

function due to degeneration of brain cells

『Korea Dementia Observatory 2016』, National Institute of Dementia(NID)

Vascular Dementia(16.8%)

the others(11.7%)

Alzheimer’s disease(71.5%)

『 Korea Dementia Observatory 2018』, National Institute of Dementia(NID), Ministry of Health and Welfare

The number of Patients with dementia over 65 years.

Prevalence of Dementiaover 65 Years.

Dementia care cost forpatient per 1 year.

725,000 10.2%38.9% of household income

20,000USD

Dementia can be prevented

Proactive response through genetic testing and early diagnosis isvery important in preventing dementia.

• 5~10 out of every 100 dementia patients can be completely cured.• It will be able to expect great treatment effect.• Systematic management can be applied to improve the quality of life of the patients.• We can cope in advance with various problems caused by the exacerbation of the disease.

Asymptomaticstage

Prodomal stage Dementia stage

Early treatmen

Late treatment

Progress

Time

Dementia(43%)

Diabetes(6%)

Heart disease(6%)

Cancer(33%)

Cerebral stroke(12%)

What are the benefits of predicting Dementia?

『2019 Dementia Guide Book』National Institute of Dementia(NID)

Early diagnosis and proper treatmentcan delay progress or improve symptoms.

APOE promoter polymorphism-219T/G is an effect modifier of the influence of APOE on Alzheimer’s Disease(AD) risk in a multiracial sample.

By adding this SNP to genetic testing, the onset risk of AD can be predicted more precisely, especially in East Asian, including Korean.

The patent registration for this variant and its test method has been completed in Korea, and the patent in the US, Europe, China, Japan, Thailand, etc. are pending.

This system uses magnetic resonance imaging (MRI) to quantify changes in the volume and thickness of brain regions associated with dementia, and to determine the prevalence and progression of Alzheimer's disease by comparing data with normal populations of the same sex and age group.

Due to applying the Korean male and female templates, the analysis errors caused by differences in the size and shape of the brains between Caucasians and East-Asians are minimized and accuracy is improved. In addition, it reduces the analysis time by fully automating the entire process from pre-processing to analysis results and improves the accuracy of diagnosis by detecting minute changes in brain atrophy that were not visible. Furthermore, we will try to apply multiracial templates in the future to raise up the accuracy of Neuro I software.

This product has been cleared by the FDA of Thailand as well as in Korea and has signed a supply contract with ‘Bumrungrad International Hospital’, ‘Samitivej Hospital’, and ‘Vejthani Hospital’ in Thailand.

InfoMeditech already has developed NeuroAi, Clinical Decision Support System based on artificial intelligence The Ministry of Food and Drug Safety is in the process of licensing medical devices.

Genetic Testing and Early Diagnosis to predict Alzheimer’s Disease. Dementia. It can be prevented by taking appropriate measures throughprediction and early diagnosis.

APOE+ Genetic Test

Brain Image Quantitative Analysis System

Clinical Decision Support System

50

40

30

20

10

Dem

entia

inci

denc

e(%

)

Age60 65 70 75 80 85

Risk of AD by Age

Average(Korean)You

Agreement on the development of artificial intelligence for predicting dementia with ‘Naver Business Platform

(NBP)’ and ‘National Research Center for Dementia (NRCD)’.

Medical Image Analysis Software Neuro I 'Cloud Version (Neuro I V1.2) Registered to the Ministry of

Food and Drug Safety.

Registered as Genetic testing agency and started APOE+ gene testing service.US / Europe / China / Japan / Thailand patent application for APOE promoter single base mutation and its

use related to Alzheimer's disease risk.

Received Patent Ownership transfer from NRCD and GIST (10-1933847 and 10-1939368)

Developed APOE+ real-time genetic test kit.

‘Neuro I’ approved in Thailand FDA.

Selected as KOTRA ‘2019 New Export Enterprise Promotion Project’.

Registered patent for 'Alzheimer's Disease Diagnosis Biomarker and its Use' (No. 10-1939368).

9

8

6

5

21

12

108

74

12

6

4

11

8

7

5

10

Selected as ‘TOP 10 New Science and Technology News of the Year’ (Korean Standard Brain Map and Brain

Image Analysis Technology) by the Korea Federation of Science and Technology Societies.

Patent registration for 'APOE promoter single base mutation and its use' related to Alzheimer's disease risk

(No. 10-1933847).

‘Neuro I’ awarded [2018 Digital Innovation Award] hosted by Hankook ilbo.

‘Neuro I’ registered as Medical Device class 2 from the Ministry of Food and Drug Safety.Acquired medical device manufacturing business license.

Participated and exhibited at the Alzheimer’s Association International Conference (AAIC).

GMP certified.

Patent application for ‘APOE promoter single base mutation and its use related to Alzheimer's disease risk’

(National Research Center for Dementia)

Patent application for ‘Alzheimer's disease Diagnosis Biomarker and its Use’

(Gwangju Institute of Science and Technology)

Participated in the 2017 BIO International Convention and exhibited ‘Neuro I’

Completed the development of 'Neuro I' prototype.

Selected by the Ministry of Science and ICT as the main developer for the ‘Development of AD Diagnosis

Artificial Intelligence System Based on Imaging Genetics’.

Signed a contract with Seoul National University for ‘technology consultation for early prediction of

Alzheimer’s disease based on genome analysis’.

Participated in 'Development of Big Data Analysis Convergence Technology and Medical Service Platform

for Early Predicting Dementia' by the Ministry of Science & ICT.

Signed the 'Alzheimer’s Disease Prediction Technology Transfer and Mutual Cooperation Agreement' with the ‘National Research Center for Dementia’.

InfoMeditech Co., Ltd. Established.

InfoMeditech

We are innovating technologies based on genome, blood and brain imaging and artificial intelligence technology to predict, early diagnosis and prevent the risk of Alzheimer's disease.

2019

2018

2017

2016

Company History

2015

7F, Dong-gung Bldg., 9, Teheran-ro 20-gil, Gangnam-gu, Seoul, Korea (06236) Tel. +82.2.501.4294 NeuroXRP : apoeplus@infomeditech.com Neuro I : neuroai@infomeditech.comwww.infomeditech.com

Early Detection and Prevention of Dementia

InfoMeditech Co., Ltd.